Literature DB >> 34249450

Methionyl-tRNA synthetase and aminoacyl-tRNA synthetases interacting multi-functional protein-lacking exon 2 as potential diagnostic biomarkers for lung cancer.

Taehee Kim1, Kyosun Lee1, Ji Hae Nahm2, Eun Young Kim1, Sang Hoon Lee1, Yoon Soo Chang1.   

Abstract

Cytological specimens from computed tomography (CT)-guided needle aspiration biopsy (CT-NAB) have relatively low sensitivity for lung cancer diagnosis. This study evaluated the usefulness of the dual immunofluorescence (IF) staining method using methionyl-tRNA synthetase (MARS), aminoacyl-tRNA synthetases interacting multi-functional protein-lacking exon 2 (AIMP2-DX2), and pan-cytokeratin (pan-CK) obtained from clinical specimens. One-hundred forty-five cytology specimens were prospectively collected from patients who underwent CT-NAB under the suspicion of lung cancer. The results of two combinations of MARS, AIMP2-DX2, and pan-CK dual IF staining were compared with those of conventional cytology by calculating the area under the curve (AUC). The results of combining dual IF with conventional cytology showed higher AUC than conventional cytology alone: cytology/MARS/AIMP2-DX2 (0.891 vs. 0.829, P = 0.003), cytology/MARS/pan-CK (0.916 vs. 0.829, P < 0.001), and cytology/AIMP2-DX2/pan-CK (0.877 vs. 0.829, P = 0.005). In specimens with non-diagnostic results in conventional cytology, MARS/AIMP2-DX2 dual IF staining showed sensitivity, specificity, and AUC of 60.0%, 86.4%, and 0.79, respectively. The dual IF staining method using two combinations of MARS, AIMP2-DX2, and pan-CK is an effective diagnostic tool that can improve the lung cancer diagnostic yield by complementing conventional cytology. AJCR
Copyright © 2021.

Entities:  

Keywords:  AIMP2-DX2; MARS; biomarker; lung cancer; pan-CK

Year:  2021        PMID: 34249450      PMCID: PMC8263685     

Source DB:  PubMed          Journal:  Am J Cancer Res        ISSN: 2156-6976            Impact factor:   6.166


  24 in total

1.  A study of immunohistochemical differential expression in pulmonary and mammary carcinomas.

Authors:  Michael Yang; Daisuke Nonaka
Journal:  Mod Pathol       Date:  2010-02-19       Impact factor: 7.842

2.  Nondiagnostic Percutaneous Transthoracic Needle Biopsy of Lung Lesions: A Multicenter Study of Malignancy Risk.

Authors:  Kyung Hee Lee; Kun Young Lim; Young Joo Suh; Jin Hur; Dae Hee Han; Mi-Jin Kang; Ji Yung Choo; Cherry Kim; Jung Im Kim; Soon Ho Yoon; Woojoo Lee; Chang Min Park
Journal:  Radiology       Date:  2018-12-18       Impact factor: 11.105

3.  Rapid on-site evaluation using telecytology: A major cancer center experience.

Authors:  Oscar Lin; Dorota Rudomina; Rusmir Feratovic; S Joseph Sirintrapun
Journal:  Diagn Cytopathol       Date:  2018-03-25       Impact factor: 1.582

4.  Dual role of methionyl-tRNA synthetase in the regulation of translation and tumor suppressor activity of aminoacyl-tRNA synthetase-interacting multifunctional protein-3.

Authors:  Nam Hoon Kwon; Taehee Kang; Jin Young Lee; Hyo Hyun Kim; Hye Rim Kim; Jeena Hong; Young Sun Oh; Jung Min Han; Min Jeong Ku; Sang Yeol Lee; Sunghoon Kim
Journal:  Proc Natl Acad Sci U S A       Date:  2011-11-21       Impact factor: 11.205

5.  Variable sensitivity and specificity of TTF-1 antibodies in lung metastatic adenocarcinoma of colorectal origin.

Authors:  Eva Compérat; Fan Zhang; Cedric Perrotin; Thierry Molina; Pierre Magdeleinat; Beatrice Marmey; Jean-Francois Régnard; Josee Audouin; Saphie Camilleri-Broët
Journal:  Mod Pathol       Date:  2005-10       Impact factor: 7.842

6.  CT-guided fine-needle aspiration cytology of solitary pulmonary nodules: a prospective, randomized study of immediate cytologic evaluation.

Authors:  L Santambrogio; M Nosotti; N Bellaviti; G Pavoni; F Radice; V Caputo
Journal:  Chest       Date:  1997-08       Impact factor: 9.410

7.  Cytokeratins in different types of human lung cancer as monitored by chain-specific monoclonal antibodies.

Authors:  J L Broers; F C Ramaekers; M K Rot; T Oostendorp; A Huysmans; G N van Muijen; S S Wagenaar; G P Vooijs
Journal:  Cancer Res       Date:  1988-06-01       Impact factor: 12.701

8.  Cancer-associated splicing variant of tumor suppressor AIMP2/p38: pathological implication in tumorigenesis.

Authors:  Jin Woo Choi; Dae Gyu Kim; Al-Eum Lee; Hye Rim Kim; Jin Young Lee; Nam Hoon Kwon; Young Kee Shin; Soon-Kyung Hwang; Seung-Hee Chang; Myung-Haing Cho; Yoon-La Choi; Jhingook Kim; Seung Hyun Oh; Bora Kim; Soo-Youl Kim; Hyo-Sung Jeon; Jae Yong Park; Hyunseok Peter Kang; Bum Joon Park; Jung Min Han; Sunghoon Kim
Journal:  PLoS Genet       Date:  2011-03-31       Impact factor: 5.917

9.  Ratio of Autoantibodies of Tumor Suppressor AIMP2 and Its Oncogenic Variant Is Associated with Clinical Outcome in Lung Cancer.

Authors:  Ji Ye Jung; Eun Young Kim; Arum Kim; Joon Chang; Nam Hoon Kwon; Youngji Moon; Eun Joo Kang; Jun Sik Sung; Hyunbo Shim; Sunghoon Kim; Yoon Soo Chang
Journal:  J Cancer       Date:  2017-05-12       Impact factor: 4.207

10.  Methionyl-tRNA synthetase overexpression is associated with poor clinical outcomes in non-small cell lung cancer.

Authors:  Eun Young Kim; Ji Ye Jung; Arum Kim; Kwangsoo Kim; Yoon Soo Chang
Journal:  BMC Cancer       Date:  2017-07-05       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.